Articles
Environmental biotech: Innovative research environment
In the first two rounds of Biotechnology Innovation Fund (BIF) grants, five companies with a clearly environmental slant obtained funding. In the first round, these included Pestat, which is commercialising immunocontraceptive mechanisms developed by the CRC for biological control of pest animals, and Orica Australia, which is developing enzyme-based methods for pesticide degradation. [ + ]
Peter Doherty: back into the fold
When Australian Nobel Laureate Peter Doherty won the 1996 Nobel Prize for Medicine, little did he know it would be his ticket back to Australia. [ + ]
The national synchrotron: ray of hope or ring of fire?
When the Victorian Government derailed the national synchrotron bidding process by announcing in June 2001 it would go it alone, it caught many people off guard. [ + ]
No plans to slow down for Austin's retiring director
When Nobel medicine laureate Dr George Snell accepted his 1980 award for identifying genetically determined cell surface immune response regulators, six peers received his thanks. One was an Australian - Prof Ian McKenzie. [ + ]
ACT feature: ACT biotech's big players
As one of the big players in the ACT's biotech scene, the John Curtin School of Medical Research (JCSMR) has already spun out at least two companies. Biotron, listed on the ASX, is one, working on two cancer diagnostic tests and a number of therapeutic agents including an antiviral for treatment of HIV. [ + ]
ACT feature: The small territory with big ideas
The Australian Capital Territory (ACT) has two big advantages when it comes to biotechnology: world-class scientists and its proximity to the Federal government. [ + ]
WA feature: Silicon valley in the west
Perth biotech pSiVida has reversed the normal flow of events by bringing in offshore technology and funding its further development out of West Australia. [ + ]
WA feature: Miners digging for biotech
Biotech companies and WA's bedrock industry - mining - appear to have little in common. [ + ]
WA feature: Could biotech be the west's next gold rush?
Western Australia's bio-industry faces more than its share of hurdles. It is isolated by geography, limited by population and dependent on a State government focussed on traditional resources and agriculture sectors. [ + ]
Eleventh hour resolution for Amrad
An air of disappointment hung over the handful of Amrad shareholders who turned up to what was supposed to be an extraordinary general meeting on May 22. [ + ]
Playtime over, now 'atomic Lego' goes to work
Nanotechnology is the newest frontier for science and engineering. Concerning itself with the science of the very, very small, nanotechnology is all about manipulation of particles at the atomic and molecular level. [ + ]
Publish? Nowadays, it's patent or perish
A cultural shift inside research labs is leading growing numbers of biotech scientists to adopt a patent first, publish later approach to their research. [ + ]
The wonderful world of cloning
Since the world's most famous cloned sheep was unveiled to a gob-smacked science community, the race has been on to build on the work. [ + ]
Our world-class clones (no bull)
On the global stage, the contribution of Australia and New Zealand to the livestock cloning arena is world class, which is only natural given the region's strong tradition in agriculture. [ + ]
A year after listing, Cellestis reflects on achievements
Cellestis is a quiet achiever in the Australian biotechnology scene. [ + ]
